Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.90
+0.30 (2.38%)
Apr 24, 2025, 1:28 PM CST

Mercury Biopharmaceutical Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-50.57-43.82-31.25-5.31-0.21
Upgrade
Depreciation & Amortization
7.454.072.750.97-
Upgrade
Stock-Based Compensation
1.241.821.13--
Upgrade
Other Operating Activities
0.460.29-0.02--
Upgrade
Change in Accounts Payable
2.570.644.860.9-
Upgrade
Change in Unearned Revenue
5.040.44---
Upgrade
Change in Other Net Operating Assets
-0.9-5.6-3.31-1.34-0.01
Upgrade
Operating Cash Flow
-34.71-42.15-25.84-4.78-0.22
Upgrade
Capital Expenditures
-10.02-12.93-68.51-6.98-
Upgrade
Sale (Purchase) of Intangibles
-1.08-0.65-0.14-0.53-
Upgrade
Investment in Securities
121.98-176.08-108.7--
Upgrade
Other Investing Activities
-2.23-4.79-8.04-0.51-
Upgrade
Investing Cash Flow
108.65-194.44-185.4-8.02-
Upgrade
Long-Term Debt Issued
--41.6--
Upgrade
Long-Term Debt Repaid
-1.45-1.07-0.99-0.39-
Upgrade
Net Debt Issued (Repaid)
-1.45-1.0740.61-0.39-
Upgrade
Issuance of Common Stock
7.1725020015.97-
Upgrade
Repurchase of Common Stock
-56.24----
Upgrade
Other Financing Activities
----0.30.15
Upgrade
Financing Cash Flow
-50.52248.93240.6115.280.15
Upgrade
Foreign Exchange Rate Adjustments
0.290.01---
Upgrade
Net Cash Flow
23.7112.3629.382.48-0.07
Upgrade
Free Cash Flow
-44.73-55.07-94.35-11.77-0.22
Upgrade
Free Cash Flow Margin
-901.17%-5331.17%-3520.60%--
Upgrade
Free Cash Flow Per Share
-0.11-0.14-0.25-0.04-0.00
Upgrade
Cash Interest Paid
0.80.710.40.01-
Upgrade
Cash Income Tax Paid
0.340.210.02--
Upgrade
Levered Free Cash Flow
-29.87-41.24-82.81-10.3-0.14
Upgrade
Unlevered Free Cash Flow
-29.37-40.8-82.56-10.3-0.14
Upgrade
Change in Net Working Capital
-6.814.57-1.530.450.01
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.